@MotherJones @mtredden not to mention undue pressure from fraudulent @Eventhescore campaign supported by industry #FDAcapitulation
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones@mtredden see shifting efficacy points, tenuous risk-benefit balance, and dangerous potential for off-label useThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones why is this controversial?Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones@mtredden No thanks.Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones Also check out last weeks@onthemedia podcast on this. Great podcast tooThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones@mtredden I can't wait to see the pharmaceutical ads. On second thought, maybe I can.Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones@mtredden editorial in JAMA this month reveals multitude of problems with the FDA's Flibanserin approvalThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@MotherJones No thanksThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.